Inside a $1 Billion Insider Selling Career: Tracking CEO Martine Rothblatt's UTHR Transactions

The Data Point

United Therapeutics CEO Martine Rothblatt sold $5.1M in UTHR stock across March 12-16, 2026. Her career insider sales now exceed $1.05 billion across 6,319 transactions.

Why It Matters for Data Analysis

Insider trading data (Form 4 filings) is one of the most structured, freely available datasets in finance. Every transaction is timestamped, priced, and categorized.

Rothblatt's selling pattern is a textbook case study:

• Career sell volume: $1.05B
• Career buy volume: $15.1M
• Transaction count: 6,319
• Beneficial ownership: 7.8% (per SC 13G/A filing)
• Exercise price: $146/share → Sold at $534-544/share

The Analysis Challenge

The naive interpretation of a $1B+ sell-to-buy ratio is bearish. But the data tells a different story:

1. Systematic cadence — Regular option exercises followed by immediate sales over years
2. Retained ownership — 7.8% beneficial ownership = over $1B in a $15B+ company
3. Timing context — Sales came after Phase III trial results and a Leerink conference appearance
4. Revenue backdrop — $3B+ revenue in 2025, targeting $4B by 2027

This is diversification, not an exit signal.

Key Takeaway

When analyzing insider transactions at scale, the sell/buy ratio alone is insufficient. You need:

• Ownership percentage context
• Transaction cadence patterns
• Corporate event correlation
• Revenue trajectory

Full analysis with transaction breakdown:

https://13finsight.com/news/rothblatt-uthr-ceo-5m-sale-post-trial-results?utm_source=devto&utm_medium=social&utm_campaign=article_ops_0318

---

Originally published at 13finsight.com